Editor notes: Celladon Corp recently posted clinical data for its Cupid Trial that did not achieve statistical significance for both primary and secondary endpoints. I spent some times studying the firm and its gene therapy. Perhaps I have some insight that can be useful for readers and the firms.
I might be wrong but most Celladon therapeutic designers are not trained as clinical docs, so chances are that these experts had not feel the inner working of the live heart or explore its inner anatomy. On the other hand, MD are mostly clinical docs without training in bioengineering and drugs design. As a team, scientists and clinicians have strengths and weaknesses that can be leveraged for synergy.